BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBRadiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
Coronavirus - BioWorld
WEBSep 12, 2024 · The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated: Vaccines and therapeutics in development. Diagnostics with U.S. FDA emergency use authorization.
BioWorld Science: The Daily Drug R&D News Source
WEBBioWorld Premium. Subscribe. Daily news focused on drug discovery, delivery and preclinical research. Coverage includes: Congress highlights, key studies from peer-reviewed journals, chemical structure images, pharmacology news that delineates drug/receptor and enzyme/target cell interactions, newly reported experimental models, and ...
Zimmer Biomet regenerates portfolio with up to $275M Embody
WEBJan 5, 2023 · Zimmer Biomet Holdings Inc. (ZBH) agreed to acquire Embody Inc. for $155 million at closing with an additional $120 million in contingent milestone payments over the next three years. The deal includes Embody’s entire portfolio of collagen-based regenerative solutions for soft tissue injuries. The transaction is expected to …
Novel anti-ChemR23 agonist MAb reprograms macrophages and …
WEBJul 31, 2023 · Novel anti-ChemR23 agonist MAb reprograms macrophages and limits metastasis in vivo. July 31, 2023. Researchers from OSE Immunotherapeutics SA have published preclinical data for the novel anti-ChemR23 monoclonal antibody (MAb) (OSE-230) with anti-inflammatory properties, being evaluated for the potential treatment of cancer.
| BioWorld
WEBSep 16, 2002 · BioWorld MedTech. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product …
Micot targets anticoagulant breakthrough with $15M round
WEBFeb 14, 2023 · New drug technology may soon deliver a breakthrough to eliminate internal bleeding caused by drug overuse. Shaanxi Micot Technology Co. Ltd.’s MT-1011 is a synthetic water-soluble small-molecule anticoagulant antagonist. After a single intravenous dose, it can bind directly to other anticoagulants to stop anticoagulant effects and restore the clotting function. Data from clinical trials ...
China - BioWorld
WEBSep 24, 2024 · China biotechs rise to challenge Ozempic, Wegovy. Sep. 17, 2024. By Marian (YoonJee) Chu. No Comments. Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China.
Organoids making their US clinical debut with CIDP drug
WEBJul 15, 2022 · Organoids making their US clinical debut with CIDP drug. The use of organoids in preclinical research has reached a tipping point, with U.S. FDA approval of the first drug to enter clinical trials on the basis of efficacy data derived only from these advanced cell models. Nine years on from securing …
Cumulus raising $50M, spinning GPR68 small molecules into GIO
WEBAug 29, 2024 · Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage ...